Advertisement
UK markets close in 3 hours 37 minutes
  • FTSE 100

    8,089.92
    +49.54 (+0.62%)
     
  • FTSE 250

    19,709.17
    -10.20 (-0.05%)
     
  • AIM

    755.20
    +0.51 (+0.07%)
     
  • GBP/EUR

    1.1670
    +0.0025 (+0.21%)
     
  • GBP/USD

    1.2511
    +0.0048 (+0.39%)
     
  • Bitcoin GBP

    51,070.50
    -2,070.93 (-3.90%)
     
  • CMC Crypto 200

    1,356.69
    -25.89 (-1.87%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,342.50
    +4.10 (+0.18%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,952.18
    -136.52 (-0.75%)
     
  • CAC 40

    8,010.51
    -81.35 (-1.01%)
     

Shire plc : Total voting rights

Total Voting Rights

January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance and Transparency Rules, notifies the market of the following:

As at December 31, 2017, the Company`s issued ordinary share capital comprised 909,782,811 ordinary shares of 5 pence each with voting rights and a further 7,357,283 ordinary shares held in treasury.

Therefore, the total number of voting rights in the Company is 909,782,811. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA`s Disclosure Guidance and Transparency Rules.

ADVERTISEMENT

Sarah Rixon

Company Secretarial Assistant

For further information please contact:

Investor Relations

Christoph Brackmann

christoph.brackmann@shire.com

+41 795 432 359

Robert Coates

rcoates@shire.com

+44 203 549 0874

Sun Kim

sun.kim@shire.com

+1 617 588 8175

Media

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Katie Joyce

kjoyce@shire.com

+1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people`s lives with medicines that have a meaningful impact on patients and all who support them on their journey.

www.shire.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via GlobeNewswire

HUG#2158915